Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepaStem in Acute on Chronic Liver Failure
NCT04229901Phase 2Terminated
- Sponsor
- Cellaïon
- Start
- Jan 2020
- Primary completion
- May 2024
- Modality
- Mesenchymal Stem Cells
- Countries
- 14
01
Overview
A Phase 2 trial of hepastem in acute-on-chronic liver failure (ACLF), sponsored by Cellaïon. Started Jan 2020; status: terminated.
02
Drugs
hepastem
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT04229901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229901.